129 related articles for article (PubMed ID: 23227451)
1. Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer.
Ashbury JE; Lévesque LE; Beck PA; Aronson KJ
Front Oncol; 2012; 2():177. PubMed ID: 23227451
[TBL] [Abstract][Full Text] [Related]
2. A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency.
Ashbury JE; Lévesque LE; Beck PA; Aronson KJ
BMC Med; 2010 Dec; 8():90. PubMed ID: 21176215
[TBL] [Abstract][Full Text] [Related]
3. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study.
Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
Breast Cancer Res; 2018 Jan; 20(1):4. PubMed ID: 29351761
[TBL] [Abstract][Full Text] [Related]
4. Selective serotonin reuptake inhibitors associated with increased mortality risk in breast cancer patients in Northern Israel.
Fischer A; Rennert HS; Rennert G
Int J Epidemiol; 2022 Jun; 51(3):807-816. PubMed ID: 35134960
[TBL] [Abstract][Full Text] [Related]
5. The Association between Selective Serotonin Reuptake Inhibitors (SSRIs) Use and the Risk of Bladder Cancer: A Nationwide Population-Based Cohort Study.
Liu YC; Chen VC; Lu ML; Lee MJ; McIntyre RS; Majeed A; Lee Y; Chen YL
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392848
[TBL] [Abstract][Full Text] [Related]
6. Use of selective serotonin reuptake inhibitors and the risk of breast cancer.
Coogan PF; Palmer JR; Strom BL; Rosenberg L
Am J Epidemiol; 2005 Nov; 162(9):835-8. PubMed ID: 16177141
[TBL] [Abstract][Full Text] [Related]
7. Interaction between tramadol and selective serotonin reuptake inhibitors: are doctors aware of potential risks in their prescription practice?
Spies PE; Pot JLWH; Willems RPJ; Bos JM; Kramers C
Eur J Hosp Pharm; 2017 Mar; 24(2):124-127. PubMed ID: 31156918
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant use and circulating prolactin levels.
Reeves KW; Okereke OI; Qian J; Tworoger SS; Rice MS; Hankinson SE
Cancer Causes Control; 2016 Jul; 27(7):853-61. PubMed ID: 27165168
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant use and breast cancer risk.
Chien C; Li CI; Heckbert SR; Malone KE; Boudreau DM; Daling JR
Breast Cancer Res Treat; 2006 Jan; 95(2):131-40. PubMed ID: 16322894
[TBL] [Abstract][Full Text] [Related]
10. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction.
Meier CR; Schlienger RG; Jick H
Br J Clin Pharmacol; 2001 Aug; 52(2):179-84. PubMed ID: 11488775
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk among users of antidepressant medications.
González-Pérez A; García Rodríguez LA
Epidemiology; 2005 Jan; 16(1):101-5. PubMed ID: 15613952
[TBL] [Abstract][Full Text] [Related]
12. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis.
Kornum JB; Nielsen RB; Pedersen L; Mortensen PB; Nørgaard M
Clin Epidemiol; 2010 Aug; 2():29-36. PubMed ID: 20865100
[TBL] [Abstract][Full Text] [Related]
13. Use of selective serotonin reuptake inhibitors and risk of re-operation due to post-surgical bleeding in breast cancer patients: a Danish population-based cohort study.
Gärtner R; Cronin-Fenton D; Hundborg HH; Pedersen L; Lash TL; Sørensen HT; Kroman N
BMC Surg; 2010 Jan; 10():3. PubMed ID: 20096133
[TBL] [Abstract][Full Text] [Related]
14. Case-Control Study Investigating the Association Between Use of Selective Serotonin Reuptake Inhibitors and Pulmonary Tuberculosis in Taiwan.
Cheng KC; Liao KF; Lin CL; Lai SW
Dose Response; 2019; 17(4):1559325819897165. PubMed ID: 31903071
[TBL] [Abstract][Full Text] [Related]
15. Serum Prolactin Levels in Patients with Major Depressive Disorder Receiving Selective Serotonin-Reuptake Inhibitor Monotherapy for 3 Months: A Prospective Study.
Park YM
Psychiatry Investig; 2017 May; 14(3):368-371. PubMed ID: 28539956
[TBL] [Abstract][Full Text] [Related]
16. The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.
Clevenger SS; Malhotra D; Dang J; Vanle B; IsHak WW
Ther Adv Psychopharmacol; 2018 Jan; 8(1):49-58. PubMed ID: 29344343
[TBL] [Abstract][Full Text] [Related]
17. Influence of selective serotonin reuptake inhibitors (SSRIs) in the development of bruxism.
Wallem A; Felipe-Spada N; Tomàs-Aliberas J
Cranio; 2022 Sep; ():1-7. PubMed ID: 36101968
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression.
Bali V; Holmes HM; Johnson ML; Chen H; Fleming ML; Aparasu RR
Pharmacotherapy; 2016 Jan; 36(1):38-48. PubMed ID: 26748455
[TBL] [Abstract][Full Text] [Related]
19. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
20. Selective Serotonin Reuptake Inhibitors (SSRIs) and Their Effect on Patient Aggression in Adult Patients in a State Psychiatric Facility: A Retrospective Analysis.
O'Donnell C; Demler TL; Trigoboff E
Innov Clin Neurosci; 2022; 19(1-3):33-38. PubMed ID: 35382065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
